Cancer Causes & Control

, Volume 24, Issue 8, pp 1595–1604

Serum folate and prostate-specific antigen in the United States

  • Yueh-Ying Han
  • Ji Young Song
  • Evelyn O. Talbott
Original paper

Abstract

Purpose

Increased evidence suggests that folate may play a significant role in cancer development. This study investigates the association between levels of serum folate and prostate-specific antigen (PSA), a biomarker for prostate cancer detection.

Methods

Using data from the 2007 to 2010 National Health and Nutrition Examination Survey, a total of 3,293 men aged 40 years and older with serum PSA and folate measures were studied. Total PSA level (tPSA) and percent free/total PSA ratio (%fPSA) were major outcomes. The alternative cutpoints were used to categorize these measures as higher risks of prostate cancer (tPSA: ≥10, ≥4, and ≥2.5 ng/ml; %fPSA: ≤15 and ≤5 %). Serum folate level was analyzed as continuous and as quintiles. Association between serum folate and PSA levels were evaluated by multivariate linear and logistic regressions.

Results

Higher serum folate levels were associated with decreased log10-transformed tPSA (β = −001, p = 0.061) and increased %fPSA (β = 0.064, p = 0.012). Adjusting for age, race/ethnicity, socioeconomic status, use of non-steroidal anti-inflammatory drugs, body mass index, and smoking status, higher serum folate (fifth quintile) was associated with lower odds of having higher tPSA (≥10 ng/ml) and lower %fPSA (≤25 %): (tPSA: odds ratio, OR associated with fifth to first quintile of folate level = 0.42; 95 % confidence interval, CI = 0.21, 0.83; p for trend = 0.022 and %fPSA: OR = 0.71; 95 % CI = 0.52, 0.95; p for trend = 0.044).

Conclusions

Results of this study suggest that higher folate status may be protective against elevated PSA levels among men without diagnosed prostate cancer. Additional epidemiologic studies are necessary to confirm our findings and to investigate potential mechanisms.

Keywords

Folate Prostate-specific antigen Prostate cancer NHANES 

Supplementary material

10552_2013_236_MOESM1_ESM.docx (24 kb)
Supplementary material 1 (DOCX 23 kb)

References

  1. 1.
    Stover PJ (2004) Physiology of folate and vitamin B12 in health and disease. Nutr Rev 62:S3–S12; discussion S3PubMedCrossRefGoogle Scholar
  2. 2.
    Ulrich CM, Potter JD (2006) Folate supplementation: too much of a good thing? Cancer Epidemiol Biomarkers Prev 15:189–193PubMedCrossRefGoogle Scholar
  3. 3.
    Choi SW, Mason JB (2000) Folate and carcinogenesis: an integrated scheme. J Nutr 130:129–132PubMedGoogle Scholar
  4. 4.
    Kim YI (2004) Will mandatory folic acid fortification prevent or promote cancer? Am J Clin Nutr 80:1123–1128PubMedGoogle Scholar
  5. 5.
    American Cancer Society (2013) Cancer Facts & Figures 2013Google Scholar
  6. 6.
    Ho E, Beaver LM, Williams DE, Dashwood RH (2011) Dietary factors and epigenetic regulation for prostate cancer prevention. Adv Nutr (Bethesda, Md.) 2: 497–510Google Scholar
  7. 7.
    Kim YI (2003) Role of folate in colon cancer development and progression. J Nutr 133:3731S–3739SPubMedGoogle Scholar
  8. 8.
    Kennedy DA, Stern SJ, Moretti M et al (2011) Folate intake and the risk of colorectal cancer: a systematic review and meta-analysis. Cancer Epidemiol 35:2–10PubMedCrossRefGoogle Scholar
  9. 9.
    Zhang S, Hunter DJ, Hankinson SE et al (1999) A prospective study of folate intake and the risk of breast cancer. JAMA, J Am Med Assoc 281:1632–1637CrossRefGoogle Scholar
  10. 10.
    Baggott JE, Oster RA, Tamura T (2012) Meta-analysis of cancer risk in folic acid supplementation trials. Cancer Epidemiol 36:78–81PubMedCrossRefGoogle Scholar
  11. 11.
    Cole BF, Baron JA, Sandler RS et al (2007) Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA, J Am Med Assoc 297:2351–2359CrossRefGoogle Scholar
  12. 12.
    Catalona WJ, Smith DS, Ratliff TL et al (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156–1161PubMedCrossRefGoogle Scholar
  13. 13.
    Barry MJ (2001) Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 344:1373–1377PubMedCrossRefGoogle Scholar
  14. 14.
    Catalona WJ, Loeb S, Han M (2006) Viewpoint: expanding prostate cancer screening. Ann Intern Med 144:441–443PubMedCrossRefGoogle Scholar
  15. 15.
    Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350:2239–2246PubMedCrossRefGoogle Scholar
  16. 16.
    Catalona WJ, Partin AW, Slawin KM et al (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA, J Am Med Assoc 279:1542–1547CrossRefGoogle Scholar
  17. 17.
    Gann PH, Ma J, Catalona WJ, Stampfer MJ (2002) Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol 167:2427–2434PubMedCrossRefGoogle Scholar
  18. 18.
    Benowitz NL, Bernert JT, Caraballo RS, Holiday DB, Wang J (2009) Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. Am J Epidemiol 169:236–248PubMedCrossRefGoogle Scholar
  19. 19.
    Chang SL, Harshman LC, Presti JC Jr (2010) Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol 28:3951–3957PubMedCrossRefGoogle Scholar
  20. 20.
    Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ (2008) The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 100:1511–1518PubMedCrossRefGoogle Scholar
  21. 21.
    Pelucchi C, Galeone C, Talamini R et al (2005) Dietary folate and risk of prostate cancer in Italy. Cancer Epidemiol Biomarkers Prev 14:944–948PubMedCrossRefGoogle Scholar
  22. 22.
    Tavani A, Malerba S, Pelucchi C et al (2012) Dietary folates and cancer risk in a network of case-control studies. Ann Oncol 23:2737–2742PubMedCrossRefGoogle Scholar
  23. 23.
    Shannon J, Phoutrides E, Palma A et al (2009) Folate intake and prostate cancer risk: a case–control study. Nutr Cancer 61:617–628PubMedCrossRefGoogle Scholar
  24. 24.
    Rossi E, Hung J, Beilby JP, Knuiman MW, Divitini ML, Bartholomew H (2006) Folate levels and cancer morbidity and mortality: prospective cohort study from Busselton, Western Australia. Ann Epidemiol 16:206–212PubMedCrossRefGoogle Scholar
  25. 25.
    Stevens VL, Rodriguez C, Pavluck AL, McCullough ML, Thun MJ, Calle EE (2006) Folate nutrition and prostate cancer incidence in a large cohort of US men. Am J Epidemiol 163:989–996PubMedCrossRefGoogle Scholar
  26. 26.
    Johansson M, Appleby PN, Allen NE et al (2008) Circulating concentrations of folate and vitamin B12 in relation to prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition study. Cancer Epidemiol Biomarkers Prev 17:279–285PubMedCrossRefGoogle Scholar
  27. 27.
    Beilby J, Ambrosini GL, Rossi E, de Klerk NH, Musk AW (2010) Serum levels of folate, lycopene, beta-carotene, retinol and vitamin E and prostate cancer risk. Eur J Clin Nutr 64:1235–1238PubMedCrossRefGoogle Scholar
  28. 28.
    Weinstein SJ, Hartman TJ, Stolzenberg-Solomon R et al (2003) Null association between prostate cancer and serum folate, vitamin B(6), vitamin B(12), and homocysteine. Cancer Epidemiol Biomarkers Prev 12:1271–1272PubMedGoogle Scholar
  29. 29.
    Collin SM, Metcalfe C, Refsum H et al (2010) Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev 19:1632–1642PubMedCrossRefGoogle Scholar
  30. 30.
    Bassett JK, Severi G, Hodge AM et al (2012) Dietary intake of B vitamins and methionine and prostate cancer incidence and mortality. Cancer Causes Control CCC 23:855–863PubMedCrossRefGoogle Scholar
  31. 31.
    Verhage BA, Cremers P, Schouten LJ, Goldbohm RA, van den Brandt PA (2012) Dietary folate and folate vitamers and the risk of prostate cancer in The Netherlands Cohort Study. Cancer Causes Control CCC 23:2003–2011PubMedCrossRefGoogle Scholar
  32. 32.
    Wien TN, Pike E, Wisloff T, Staff A, Smeland S, Klemp M (2012) Cancer risk with folic acid supplements: a systematic review and meta-analysis. BMJ Open 2:e000653PubMedCrossRefGoogle Scholar
  33. 33.
    Iyer R, Tomar SK (2009) Folate: a functional food constituent. J Food Sci 74:R114–R122PubMedCrossRefGoogle Scholar
  34. 34.
    Piyathilake CJ, Robinson CB, Cornwell P (2007) A practical approach to red blood cell folate analysis. Anal Chem Insights 2:107–110PubMedGoogle Scholar
  35. 35.
    Ulrich CM, Potter JD (2007) Folate and cancer–timing is everything. JAMA, J Am Med Assoc 297:2408–2409CrossRefGoogle Scholar
  36. 36.
    Bistulfi G, Vandette E, Matsui S, Smiraglia DJ (2010) Mild folate deficiency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells. BMC Biol 8:6PubMedCrossRefGoogle Scholar
  37. 37.
    Shabbeer S, Williams SA, Simons BW, Herman JG, Carducci MA (2012) Progression of prostate carcinogenesis and dietary methyl donors: temporal dependence. Cancer Prev Res (Phila) 5:229–239CrossRefGoogle Scholar
  38. 38.
    Petersen LF, Brockton NT, Bakkar A et al (2012) Elevated physiological levels of folic acid can increase in vitro growth and invasiveness of prostate cancer cells. BJU Int 109:788–795PubMedCrossRefGoogle Scholar
  39. 39.
    Bistulfi G, Foster BA, Karasik E et al (2011) Dietary folate deficiency blocks prostate cancer progression in the TRAMP model. Cancer Prev Res (Phila) 4:1825–1834CrossRefGoogle Scholar
  40. 40.
    Tomaszewski JJ, Cummings JL, Parwani AV et al (2011) Increased cancer cell proliferation in prostate cancer patients with high levels of serum folate. Prostate 71:1287–1293PubMedGoogle Scholar
  41. 41.
    Henderson RJ, Eastham JA, Culkin DJ et al (1997) Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst 89:134–138PubMedCrossRefGoogle Scholar
  42. 42.
    Ulrich CM (2008) Folate and cancer prevention–where to next? Counterpoint. Cancer Epidemiol Biomarkers Prev 17:2226–2230PubMedCrossRefGoogle Scholar
  43. 43.
    Jackson MD, Tulloch-Reid MK, McFarlane-Anderson N et al (2012) Complex interaction between serum folate levels and genetic polymorphisms in folate pathway genes: biomarkers of prostate cancer aggressiveness. Genes Nutr 8:199–207PubMedCrossRefGoogle Scholar
  44. 44.
    Bostwick DG, Burke HB, Djakiew D et al (2004) Human prostate cancer risk factors. Cancer 101:2371–2490PubMedCrossRefGoogle Scholar
  45. 45.
    Rota M, Scotti L, Turati F et al (2012) Alcohol consumption and prostate cancer risk: a meta-analysis of the dose-risk relation. Eur J Cancer Prev 21:350–359PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Yueh-Ying Han
    • 1
  • Ji Young Song
    • 2
  • Evelyn O. Talbott
    • 2
  1. 1.Department of Pediatrics, School of MedicineUniversity of PittsburghPittsburghUSA
  2. 2.Department of Epidemiology, Graduate School of Public HealthUniversity of PittsburghPittsburghUSA

Personalised recommendations